Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90 Y microsphere brachytherapy in the treatment of hepatic malignancies.

Yttrium-90 microsphere brachytherapy of the liver exploits the distinctive features of the liver anatomy to treat liver malignancies with beta radiation and is gaining more wide spread clinical use. This report provides a general overview of microsphere liver brachytherapy and assists the treatment team in creating local treatment practices to provide safe and efficient patient treatment. Suggestions for future improvements are incorporated with the basic rationale for the therapy and currently used procedures. Imaging modalities utilized and their respective quality assurance are discussed. General as well as vendor specific delivery procedures are reviewed. The current dosimetry models are reviewed and suggestions for dosimetry advancement are made. Beta activity standards are reviewed and vendor implementation strategies are discussed. Radioactive material licensing and radiation safety are discussed given the unique requirements of microsphere brachytherapy. A general, team-based quality assurance program is reviewed to provide guidance for the creation of the local procedures. Finally, recommendations are given on how to deliver the current state of the art treatments and directions for future improvements in the therapy.

[1]  B. Coursey,et al.  Radioassays of yttrium-90 used in nuclear medicine. , 1993, Nuclear medicine and biology.

[2]  Kenneth G. Thurston,et al.  Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. , 2006, Journal of vascular and interventional radiology : JVIR.

[3]  I Clairand,et al.  DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R. T. Ten Haken,et al.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Braunstein,et al.  Clinical evaluation of an instant kit for preparation of 99mTc-MAA for lung scanning. , 1973, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  A. Benson,et al.  Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. , 2007, International journal of radiation oncology, biology, physics.

[7]  W. Dezarn,et al.  Resin 90Y microsphere activity measurements for liver brachytherapy. , 2007, Medical physics.

[8]  R. Collé,et al.  Standardization of 63Ni by 4πβ Liquid Scintillation Spectrometry With 3H-Standard Efficiency Tracing , 1997, Journal of research of the National Institute of Standards and Technology.

[9]  W. Dezarn,et al.  SU‐FF‐T‐380: Significant Differences Exist Across Institutions in 90Y Activities Compared to Reference Standard , 2007 .

[10]  W. Lau,et al.  Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. , 1995, International journal of radiation oncology, biology, physics.

[11]  J. Welsh,et al.  Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. , 2006, International journal of radiation oncology, biology, physics.

[12]  C. Nutting,et al.  Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. , 2006, International journal of radiation oncology, biology, physics.

[13]  L A DeWerd,et al.  A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. , 2007, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[14]  Cedric X. Yu,et al.  Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. , 2004, Medical physics.

[15]  M H Loew,et al.  Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy. , 1998, Medical physics.

[16]  C. Breedis,et al.  The blood supply of neoplasms in the liver. , 1954, The American journal of pathology.

[17]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[18]  D. Day,et al.  Chemical durability of Y2O3-Al2O3-SiO2 glasses for the in vivo delivery of beta radiation. , 1993, Journal of biomedical materials research.

[19]  M. Dell,et al.  Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  A. Li,et al.  Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer , 1997, European Journal of Nuclear Medicine.

[21]  F. Mourtada,et al.  WE‐D‐BRB‐02: Comparing a Grid‐Based Boltzmann Solver with Monte Carlo Simulation for Voxel‐Based Therapeutic Radionuclide Dose Calculations , 2009 .

[22]  K. Kossert,et al.  Activity standardization by liquid scintillation counting and half-life measurements of 90Y. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[23]  S. Houle,et al.  Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  J Y Wong,et al.  A radionuclide therapy treatment planning and dose estimation system. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  Michael G Stabin,et al.  Update: the case for patient-specific dosimetry in radionuclide therapy. , 2008, Cancer biotherapy & radiopharmaceuticals.

[26]  A. Li,et al.  Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours , 1996, European Journal of Nuclear Medicine.

[27]  C. Baldock,et al.  Development of activity standard for 90 Y microspheres. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[28]  T. Mackie,et al.  EGS4 Monte Carlo determination of the beta dose kernel in water. , 1990, Medical physics.

[29]  Shawn D. Pautz,et al.  Discontinuous Finite Element SN Methods on Three-Dimensional Unstructured Grids , 2001 .

[30]  Bruce Thomadsen,et al.  Inter-society standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACRO. , 2003, Critical reviews in oncology/hematology.

[31]  V. Gebski,et al.  Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  D J Simpkin,et al.  The spatial and energy dependence of bremsstrahlung production about beta point sources in H2O. , 1992, Medical physics.

[33]  R. Collé,et al.  Construction and implementation of the NIST triple-to-double coincidence ratio (TDCR) spectrometer. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[34]  B. Zimmerman,et al.  KEY COMPARISON: Report of the CIPM Key Comparison CCRI(II)-K2.Y-90 , 2005 .

[35]  J. Geschwind,et al.  Radioembolization with 90Y Microspheres: Angiographic and Technical Considerations , 2007, CardioVascular and Interventional Radiology.

[36]  L E Williams,et al.  A CT assisted method for absolute quantitation of internal radioactivity. , 1996, Medical physics.

[37]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[38]  B. Zimmerman,et al.  Experimental determination of calibration settings for plastic syringes containing solutions of 90Y using commercial radionuclide calibrators. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[39]  Mark J Rivard,et al.  Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121. , 2010, Medical physics.

[40]  W. Dezarn Quality assurance issues for therapeutic application of radioactive microspheres. , 2008, International journal of radiation oncology, biology, physics.

[41]  K. Koral,et al.  Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  Yuni Dewaraja,et al.  Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  R. T. Ten Haken,et al.  Radiation-associated liver injury. , 2010, International journal of radiation oncology, biology, physics.

[44]  Maggie A Flower,et al.  RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry. , 2003, Cancer biotherapy & radiopharmaceuticals.

[45]  C. Nutting,et al.  Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. , 2004, International journal of radiation oncology, biology, physics.

[46]  A. Li,et al.  Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. , 1997, The British journal of radiology.

[47]  B. Wessels,et al.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  B. Thomadsen,et al.  Technical note: the calibration of 90Y-labeled SIR-Spheres using a nondestructive spectroscopic assay. , 2008, Medical physics.

[49]  D. E. Wessol,et al.  Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system , 2004, Physics in medicine and biology.

[50]  Gerald L. DeNardo,et al.  Quantitative SPECT of uptake of monoclonal antibodies. , 1989, Seminars in nuclear medicine.

[51]  G Sgouros,et al.  Implementation and evaluation of patient-specific three-dimensional internal dosimetry. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  W E Bolch,et al.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.